Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its key secondary…
Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study (NCT04573478) of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients…
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023. “We delivered another quarter of outstanding results driven by accelerating performance across our non-Humira growth platform, which is…
RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2023. “Our strong results this quarter reflect…
UnitedHealthcare announced its 2024 Individual and Family ACA Marketplace Plans, which feature affordable coverage, convenient access to care and a wide range of benefits in 26 states. Consumers can enroll…
Cardinal Health (NYSE: CAH) has been named among the 100 Best Corporate Citizens, a prestigious annual ranking by 3BL Media that assesses the environmental, social and governance (ESG) transparency and performance of the…
Aetna®, a CVS Health® company (NYSE: CVS), announced today that 87 percent of its Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4…
Kaiser Permanente issued the following statement from Greg A. Adams, chair and chief executive officer of Kaiser Permanente, as part of the announcement of a settlement agreement with the Department of Managed…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a…
Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and…
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and three pipeline candidates in more than 15…